AI Earnings Predictions for Anika Therapeutics Inc. (ANIK)

EX-99.1

2 exh_991.htm

PRESS RELEASE

EdgarFiling

EXHIBIT 99.1

Anika Reports Third Quarter 2026 Financial Results

Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue

Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product

Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.

Total revenue for the third quarter was $30.6 million, compared with $27.8 million in the prior-year period, representing 10% year over year growth. Performance was driven by continued Commercial Channel growth and steady Original Equipment Manufacturer (OEM) Channel execution, with Commercial Channel revenue of $14.0 million, up approximately 17% year over year, and OEM Channel revenue of $16.6 million, up approximately 5% year over year.

Third quarter results reflected continued progress on Anika’s strategy to accelerate revenue growth, strengthen operations and advance the pipeline. International viscosupplement revenue increased 19% year over year, total Regenerative Solutions revenue increased 12%, and Integrity revenue grew both sequentially and by more than 30% year over year despite more market-wide seasonality than usual in the summer months. Strong Integrity performance was supported in part by the larger implant sizes introduced in the fourth quarter of 2025 and first quarter of 2026, respectively, which expanded use into other tendon applications including foot & ankle and knee.

“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption,” said Steve Griffin, President and Chief Executive Officer. “Third quarter results reflect the continued execution against these priorities and represent key milestones to improve durable growth and drive sustained profitability. Taken together, this progress reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations.”

Accelerating Revenue Growth Anika delivered a solid third quarter, highlighted by growth across both channels and continued progress on key pipeline and operational priorities. Through the first nine months, Anika has delivered double-digit revenue growth in both channels, with Commercial Channel revenue increasing 15% and OEM Channel revenue increasing 11% year to date. As part of the Company’s strategy to drive sustainable long-term growth, an enhanced long-term commercial agreement with improved economics has been secured increasing revenue visibility and unlocking additional value in one of our non-orthopedic product franchises.

Strengthening Operational Discipline Operational discipline remains central to Anika’s value creation strategy. Gross margin improved meaningfully year over year driven by manufacturing productivity offset partially by product mix from the reintroduction of Hyalomatrix®, a Hyaff wound product. Anika continues to improve manufacturing execution through stronger production planning, process improvements and sourcing flexibility, including FDA approval of new aseptic manufacturing processes and validation of a second cross-link filler. Because demand has exceeded forecasts, the Company has significantly increased throughput. Unit volumes on Anika’s cross-link line are now more than 50% above 2022 levels, and further opportunity exists to expand output. As demand continues to grow, the Company is increasing production and building safety stock to support future growth, which is expected to drive additional productivity gains and gross margin improvement over time.

Advancing the Pipeline In September, enrollment in the Cingal bioequivalence study was completed. Following completion of the clinical study report and chemistry, manufacturing and controls (CMC) work required to file HA as a drug, Anika expects the Cingal new drug application (NDA) to be submitted before year-end 2027.

In October, the Company received formal notification from the FDA that the Hyalofast® pre-market approval (PMA) application is not approvable, primarily based on the clinical data included in the submission. Anika continues to believe strongly in Hyalofast’s potential in the U.S. market and is continuin

EX-99.1

2 exh_991.htm

PRESS RELEASE

EdgarFiling

EXHIBIT 99.1

Anika Reports Second Quarter 2026 Financial Results

Commercial Channel Revenue Increased 17% to a Record $13.9 Million

Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020

Raising Full-Year 2026 Financial Guidance and Revising 2027 Revenue Forecast

BEDFORD, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early-intervention orthopedics, today announced financial results for the second quarter of 2026.

Total revenue for the second quarter was $32.6 million, compared to $28.2 million in the prior-year period. Performance was driven by record Commercial Channel revenue of $13.9 million, representing organic growth of 17% year-over-year, and continued strength in the OEM Channel supported by favorable US Monovisc and Orthovisc sales.

Gross profit for the second quarter was $21.2 million, compared to $14.4 million in the prior-year period. Gross margin expanded to 65%, reflecting higher sales volume, increased manufacturing production and improved sales mix.

Total operating expenses were $18.3 million, compared to $18.5 million in the prior-year period. Operating expense performance reflected continued cost discipline across the business while maintaining targeted investments to support commercial growth and strategic development programs. Excluding approximately $0.8 million of one-time severance-related expenses, adjusted operating expenses were $17.5 million, representing a decline of 6% versus the prior-year period.

Net income was $3.3 million for the second quarter, representing a 10% margin. Adjusted EBITDA was $7.1 million, representing a 22% Adjusted EBITDA margin reflecting continued benefits from commercial growth, gross margin expansion, and disciplined expense management.

"Our second quarter results mark a positive step forward in improving the performance of our business. We achieved record Commercial Channel revenue, substantial gross margin expansion, and our highest adjusted EBITDA since 2020. The actions we initiated earlier this year are delivering early gains as we continue to drive operational excellence throughout the Company. Additionally, our growth has diversified across channels and geographies, highlighted by a record quarter of international revenue.” said Steve Griffin, President and Chief Executive Officer.

“Our OEM business continues to perform well, supported by stronger transfer unit volumes driven by J&J DePuy Synthes, order timing across both the Monovisc and Orthovisc product lines, favorable U.S. Monovisc end market sales, and continued international growth. These drivers increased production, throughput and manufacturing yields, resulting in meaningful gross margin expansion and operating leverage. Combined with disciplined expense management, a 20% reduction in G&A expenses (or 30% excluding one-time severance-related charges), and lower stock-based compensation expense, these improvements are translating into meaningful profitability gains.

Given our first-half performance, we are raising our full-year financial outlook. Most notably, we are raising our adjusted EBITDA margin outlook to 13%-17%, driven by improved operating leverage. Our improved outlook is supported by favorable OEM sales trends, continued Commercial Channel growth, operational improvements, and disciplined cost management. While we expect some moderation in revenue and profitability during the second half relative to the strong first half, reflecting the timing of certain OEM orders, we remain encouraged by the underlying trends in the business and our ability to deliver improved full-year performance. We are still early in our company-wide transformation, yet the results achieved in the first half reinforce that our strategy is working and that disciplined execution against our mission is creating sustainable value.

As we continue to advance toward filing the Cingal New Drug Application (“NDA”) we’re making steady progress on the bioequivalence study for Triamcinolone Hexacetonide and are accelerating the necessary Chemistry, Manufacturing and Controls (“CMC”), activities required to file Cingal as a drug-drug combination product. Additionally, we remain actively engaged with the U.S. Food and Drug Administration (“FDA”) on Hyalofast, with discussions focusing primarily on the co-primary clinical endpoints within the Premarket Approval (“PMA”) submission.

Given the timing uncertainty that remains in our regulatory review process, particularly as our discussions with the FDA on Hyalofast evolve, we are adopting a new revenue guidance practice. Going forward, our forecast will only include revenue from products that have received regulatory approval or clearance. As a result, our 2027 Commercial Channel revenue guidance no longer inclu

EX-99.1

2 exh_991.htm

PRESS RELEASE

EdgarFiling

EXHIBIT 99.1

Anika Reports First Quarter 2026 Financial Results

Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing

Delivered 64% gross margin, +8 points year over year, driven by improved operational execution

Operational transformation generating early wins, delivering $4 million of adjusted EBITDA

BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.

Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-year period, representing growth of 13%. Growth was driven by strength across both channels, with OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12% year-over-year.

Gross profit for the first quarter was $19.0 million, compared to $14.7 million in the prior-year period. Gross margin improved to 64.2%, compared to 56.1% in the first quarter of 2025, driven by operational execution, ongoing margin improvement initiatives and favorable product mix.

Total operating expenses were $24.5 million, compared to $19.0 million in the prior-year period, primarily reflecting $4.9 million of one-time severance costs. Remaining increases were largely related to investments in operations and research and development expenses to support ongoing programs.

Adjusted EBITDA for the first quarter of 2026 was $4.3 million, compared to $0.1 million in the first quarter of 2025, reflecting strong gross margin expansion and disciplined operational execution.

“Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization,” said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. “We delivered a strong start to 2026, highlighted by double-digit revenue growth and gross margin expansion, which improved adjusted EBITDA. These results were led by strong growth in our Commercial Channel with Regenerative Solutions increasing 20% year over year, driven by 35% US procedure growth from Integrity, which generated $1.8 million in revenue during the quarter. In addition, OEM Channel performance reflected a combination of favorable order timing, lower 2025 sales volume, and solid execution by our teams to start 2026, contributing to a 14% revenue increase year over year.

Our margin performance in the first quarter demonstrates the leverage in our business model as volume scales and operational initiatives take hold, including the deployment of lean manufacturing principles that are enabling our teams to increase throughput and drive improved performance. These initiatives are designed to support our operations as we advance our portfolio through FDA review and position the company to scale production in anticipation of future growth. At the same time, we continue to make targeted investments across our regenerative pipeline and commercial business to position Anika for sustainable, profitable long-term growth.”

First Quarter 2026 Business Highlights and Current Business Updates

International OA Pain Management grew 9% in the first quarter reaching $8.9 million, led by continued regional expansion and improved market share. Integrity continued to demonstrate strong momentum, with U.S. sales execution driving a 35% increase in procedures year over year and generating $1.8 million in revenue. Growth was driven by sustained surgeon adoption in the U.S., the successful launch of larger Integrity sizes that expand addressable tendon applications, and increasing international penetration. Hyalofast PMA engagement with FDA continues to progress and review timeline remains in line with the previously provided timeline. Cingal bioequivalence study enrollment remains on track in preparation for an FDA NDA submission including necessary CMC work to support HA as a drug. OEM channel year over year growth driven by order timing of non-orthopedic and US OA Pain Management products including continued strong Monovisc demand Targeted operational investments improving productivity, discipline, and scalability First Quarter 2026 Continuing Operations Financial Summary

Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share Adjusted net income from continuing operations1 $3.8 million, $0.27 per diluted share Adjusted EBITDA1 $4.3 million Cash and cash equivalents $41.0 million as of March 31, 2026

1 See description of non-GAAP fin